CAR-T Cell Therapy Gemcitabine Combination Solid Tumors

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current CAR-T cell therapy is ineffective for treating solid tumors due to difficulties in homing CAR-T cells to tumor tissues and the complex tumor microenvironment, which differs from hematologic tumors.

Innovation Solution

Administering immune effector cells expressing a receptor recognizing a tumor antigen in combination with Gemcitabine to enhance anti-tumor efficacy, allowing for various administration schedules and routes, including simultaneous, sequential, or combined administration of both components.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If CAR-T cell therapy is used to treat solid tumors, then the therapeutic effect is improved, but the ability of CAR-T cells to reach tumor cells is reduced due to difficulties in homing to tumor tissue

Engineering Contradiction:

Improvetherapeutic effectVSAvoidhoming speed

Core Design Contradiction:

ReliabilityVSSpeed

Solution Approach 1:

The patent applies preliminary action by pre-treating with Gemcitabine to modify the tumor microenvironment before administering CAR-T cells. This pre-modification of the tumor site creates favorable conditions for subsequent CAR-T cell infiltration and activity, addressing the homing difficulty in advance.

Inventive Principle:

Principle #10Preliminary action

2Reliability

If CAR-T cell therapy is used to treat solid tumors, then the therapeutic effect is improved, but the complex tumor microenvironment reduces the effectiveness of CAR-T cells through interactions between tumor cells, stromal cells, and immunosuppression

Engineering Contradiction:

Improvetherapeutic effectVSAvoidimmunosuppression in tumor microenvironment

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful immunosuppressive tumor microenvironment into a beneficial state by using Gemcitabine to modify it. The drug transforms the previously harmful complex microenvironment into a more favorable condition for CAR-T cell therapy, turning the obstacle into an advantage.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Device complexity

If CAR-T cell therapy alone is used, then the treatment is simple, but the therapeutic effect on solid tumors is insufficient due to the complex and dynamic tumor microenvironment

Engineering Contradiction:

Improvetreatment complexityVSAvoidtherapeutic effect

Core Design Contradiction:

Device complexityVSReliability

Solution Approach 1:

The patent merges CAR-T cell therapy with Gemcitabine chemotherapy into a combined treatment regimen. This combination leverages the strengths of both approaches: Gemcitabine modifies the tumor microenvironment while CAR-T cells provide targeted immunotherapy, achieving synergistic anti-tumor effects.

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20220152101A1Cellular immunotherapy combination

Publication Date: 2022.05.19 CRAGE MEDICAL CO LTD

AI summary

Disclosed is a tumor treatment method, wherein immune effector cells and Gemcitabine are administered to an individual with tumor, and the immune effector cells express receptors having a tumor-specific antigen. Also disclosed is a tumor treatment kit, wherein the kit comprises 1) immune effector cells expressing receptors that recognize tumor antigens; 2) Gemcitabine; 3) a container for containing the substances of 1) and 2) described above; and 4) drug administration instructions for using the kit to treat a tumor.